RHBDD1 and colorectal carcinoma: RHBDD1 also improves the expression of the β-catenin target gene, ZEB1. Furthermore, the protein level of RHBDD1 positively correlated with ZEB1. Thereby, RHBDD1 has been proposed as a novel therapeutic target and/or a clinically useful biomarker for metastatic CRC (Table 1).